Project description
Insight into therapy-related malignancies
Childhood cancer survivors often present with therapy-related malignancies as a result of exposure to chemotherapy or radiotherapy. However, the mechanistic details of how these secondary malignancies emerge are poorly understood. The scope of the EU-funded SecondCANCERinKIDS project is to investigate how mutations accumulate in hematopoietic stem cells and give rise to therapy-related myeloid malignancies (t-MNs). For this purpose, scientists will study hematopoietic cell lineages in children before and after they receive chemotherapy to determine whether the malignant clones pre-existed or were generated as a consequence of treatment. The results will show how chemotherapy affects blood composition and provide novel insights into the origin of cancer.
Objective
Therapy-related malignancies are a major cause of long-term mortality among childhood cancer survivors. However, it is unclear how exposure to chemo- and/or radiotherapy early in life induces carcinogenesis. My aim is to determine the mechanisms and rate-limiting steps underlying the genesis of second malignancies in childhood cancer survivors. For this, we will focus on studying the etiology of therapy-related myeloid malignancies (t-MNs). I have pioneered methods to characterize mutation accumulation in single stem cells and study clonal lineages in the human hematopoietic system. My lab is embedded in Europe’s largest childhood cancer center, providing the opportunity to apply our techniques to unique patient material. In Objective 1, we will dissect the life history of t-MN and study its cellular origin. Our key question is: Was the original t-MN clone already present before chemotherapy exposure, or generated as a consequence thereof? We will address this by tracking back clonal lineages in the hematopoietic tissue of patients using the mutations present in their second cancers. In Objective 2, we will study the mutational consequences of chemotherapy in normal hematopoietic cells of children before and after they received treatment. Our key question is: Is enhanced mutagenesis rate limiting for t-MN development? To address this, we will perform in-depth mutational analyses and in vitro validations. In Objective 3, we will determine phenotypic effects of chemotherapy on population dynamics of blood. Our key question is: how does chemotherapy affect selection dynamics and clonal composition of blood? To address this, we will integrate clonal histories and lineage contributions using somatically acquired mutations. Our unique methodology and anticipated novel insights will not contribute to improved survival of children with cancer, but also to increased fundamental knowledge on the origin of cancer.
Fields of science
Programme(s)
Funding Scheme
ERC-COG - Consolidator GrantHost institution
3584CS Utrecht
Netherlands